7th Annual General Meeting: Shareholders approve all proposals

   Galenica AG / Key word(s): AGMEGM
   7th Annual General Meeting: Shareholders approve all proposals
   10.04.2024 / 17:29 CET/CEST
     ____________________________________________________________

   
   Press release

   The seventh Annual General Meeting of Galenica Ltd. was held on
   10 April 2024 at the Kursaal in Bern. The shareholders approved
   all the proposals put forward by the Board of Directors. They
   also approved the proposed dividend of CHF 2.20 per share. All
   members of the Board of Directors were re-elected for a term of
   office of one year.

   The seventh Annual General Meeting of Galenica Ltd. was attended
   by 418 shareholders representing a total of 73.3% of the
   registered voting shares of Galenica Ltd.

   Re-elections to the Board of Directors and the Remuneration
   Committee

   Dr Markus R. Neuhaus, Pascale Bruderer, Bertrand Jungo, Judith
   Meier, Prof. Dr med. Solange Peters, Dr Andreas Walde and Jörg
   Zulauf were re-elected as members of the Board of Directors for a
   term of office of one year. Dr Markus R. Neuhaus was re-elected
   as Chairman of the Board of Directors for a term of office of one
   year.

   Bertrand Jungo, Pascale Bruderer, Prof. Dr med. Solange Peters
   and Dr Andreas Walde were re-elected as members of the
   Remuneration Committee for a term of office of one year, with the
   Board of Directors re-appointing Bertrand Jungo as its chairman.

   Approval of the 2023 financial statements and discharge of the
   Board of Directors and Executive Committee

   The shareholders also voted in favour of the proposals put
   forward by the Board of Directors for the other agenda items: For
   example, the 2023 Annual Financial Statements of Galenica Ltd.,
   the Management Report and the 2023 consolidated Financial
   Statements of the Galenica Group were approved and the actions of
   the members of the Board of Directors and the Executive Committee
   for the 2023 financial year were ratified. In a consultative
   vote, the shareholders endorsed the Remuneration Report 2023,
   with 94% voting in favour. For the first time, shareholders also
   approved the report on non-financial matters pursuant to Article
   964a of the Swiss Code of Obligations with 88.7% voting in
   favour. The proposed binding maximum total remuneration for 2025
   for the members of the Board of Directors and the Executive
   Committee was also approved with 95.6% and 96.9% votes in favour,
   respectively.

Sustainable and stable dividend

   The Annual General Meeting also approved the dividend at the
   prior-year level of CHF 2.20 per share proposed by the Board of
   Directors. Half (CHF 1.10 per share) is paid out from the capital
   contribution reserve and the other half from retained earnings.
   This corresponds to a total expected distribution of CHF 109.6
   million. Galenica strives to achieve strong and sustainable
   dividend growth and plans to pay a dividend equal at least to the
   previous year's level in 2024. The dividend for the 2023
   financial year will be paid to shareholders from 16 April 2024.

   Dates for the diary
   23 May 2024:     Galenica Group sales update
   6 August 2024:   Galenica Group half-year results 2024
   24 October 2024: Galenica Group sales update

For further information, please contact:

   Media Relations:
   E-Mail: media@galenica.com
   Tel. +41 58 852 85 17 Investor Relations:
   E-Mail: investors@galenica.com
   Tel. +41 58 852 85 31

   Welcome to the Galenica network!
   Our ambition is to meet the needs of patients and customers in
   the Swiss healthcare market in a seamless, efficient and
   personalised way. To achieve this, we operate the Galenica
   network with over 20 Business Units, the strongest partners in
   the Swiss healthcare market. We offer fully integrated solutions
   both for customers and patients as well as for pharmacies,
   drugstores, medical practices, hospitals, retirement and nursing
   homes, home care providers, wholesalers, pharmaceutical
   companies, health insurance funds and other partners.
   Galenica is listed on the Swiss Stock Exchange (SIX Swiss
   Exchange, GALE, security number 36,067,446). Additional
   information concerning Galenica can be found at www.galenica.com.

____________________________________________________________

   End of Media Release
     ____________________________________________________________

   Language:    English
   Company:     Galenica AG
                Untermattweg 8
                3027 Bern
                Switzerland
   Phone:       +41 058 852 81 11
   E-mail:      info@galenica.com
   Internet:    https://www.galenica.com
   ISIN:        CH0360674466
   Listed:      SIX Swiss Exchange
   EQS News ID: 1875561

   End of News EQS News Service
     ____________________________________________________________

1875561 10.04.2024 CET/CEST